Department of Orthopaedics, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Road Jing Wu Wei Qi, Jinan, 250021, Shandong, China.
Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Yishan Road 600, Shanghai, 200233, China.
J Orthop Surg Res. 2019 Aug 27;14(1):272. doi: 10.1186/s13018-019-1317-4.
Numerous quantitatively based studies measuring the association between gout and the risk of fractures remain inconclusive. In order to determine whether gout could increase the risk of fractures, a meta-analysis was performed systematically.
Electronic databases, MEDLINE/PubMed, Embase, and Cochrane Library were systematically searched to identify studies evaluating the association of gout and the risk of fractures. No restrictions on language, publication date, or journal of publication were imposed. Meta-analysis was performed to pool the outcome estimates of interest such as fracture incidence, fracture risk, and fracture risk in different sites and at different time points in the follow-up period.
Screening determined that seven studies involving a total of 684,964 participants (151,002 in the gout group and 533,962 in the control group) were deemed viable for inclusion in the meta-analysis. The results of the analysis showed that gout would not significantly have a relatively higher risk of any fracture (RR = 1.11, 95% CI 0.98-1.26). Subgroup analysis showed consistent results for sexuality (female: RR = 1.13, 95% CI 0.93-1.37; male: RR = 0.99, 95% CI 0.91-1.07) and several occurring sites (humerus, wrist, vertebra, hip, upper limbs, and lower limbs). Additionally, the results demonstrated that urate-lowering drugs prescribed early during disease had neither adverse nor beneficial effect on the long-term risk of fractures (RR = 0.89, 95% CI 0.76-1.05).
This meta-analysis confirmed that gout was not associated with an increased risk of fractures. Urate-lowering drugs prescribed early during the course of disease had neither adverse nor beneficial effect on the long-term risk of fractures.
大量基于定量研究的文献表明,痛风与骨折风险之间存在关联,但结论仍不一致。为了明确痛风是否会增加骨折风险,我们进行了系统的荟萃分析。
系统检索电子数据库(MEDLINE/PubMed、Embase 和 Cochrane Library),以确定评估痛风与骨折风险相关性的研究。本研究未对检索文献的语言、出版日期或期刊来源进行限制。采用荟萃分析对骨折发生率、骨折风险、不同部位骨折风险以及随访期间不同时间点骨折风险等感兴趣结局的研究结果进行汇总。
筛选确定了 7 项共纳入 684964 名参与者的研究(痛风组 151002 例,对照组 533962 例)符合纳入荟萃分析的条件。分析结果显示,痛风患者发生任何类型骨折的风险并未显著升高(RR=1.11,95%CI 0.98-1.26)。亚组分析显示,无论性别(女性:RR=1.13,95%CI 0.93-1.37;男性:RR=0.99,95%CI 0.91-1.07)还是骨折发生部位(肱骨、腕骨、椎体、髋部、上肢和下肢),结果均一致。此外,结果表明疾病早期应用降尿酸药物治疗对骨折长期风险既无不良影响也无有益影响(RR=0.89,95%CI 0.76-1.05)。
本荟萃分析证实痛风与骨折风险增加无关。疾病早期应用降尿酸药物治疗对骨折长期风险既无不良影响也无有益影响。